Internal Reference Number: FOI_9015
Date Request Received: 05/11/2025 00:00:00
Date Request Replied To: 19/11/2025 00:00:00
This response was sent via: By Email
Request Summary: Oncology
Request Category: Researcher
| Question Number 1: I have a freedom of information request regarding the treatment of certain types of cancer. Could you please answer the following questions. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Atezolizumab (Tecentriq) • Durvalumab (Imfinzi) • Nivolumab (Opdivo) • Pembrolizumab (Keytruda) • Chemotherapy • Radiotherapy • Chemotherapy AND Radiotherapy • Osimertinib | |
| Answer To Question 1: • Atezolizumab (Tecentriq) 0 • Durvalumab (Imfinzi) <5 • Nivolumab (Opdivo) 0 • Pembrolizumab (Keytruda) <5 • Chemotherapy <5 • Radiotherapy- not given at SFT • Chemotherapy AND Radiotherapy- see above • Osimertinib 5 | |
| Question Number 2: How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma? | |
| Answer To Question 2: Not treated at this Trust | |
| Question Number 3: How many patients has your Trust treated in total in the past 3 months for • Stage 2 Non-Small Cell Lung Cancer • Stage 3 Non-Small Cell Lung Cancer | |
| Answer To Question 3: • Stage 2 Non-Small Cell Lung Cancer <5 • Stage 3 Non-Small Cell Lung Cancer 6 | |
| Question Number 4: How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Atezolizumab • Pembrolizumab monotherapy • Pembrolizumab with chemotherapy • Nivolumab • Osimertinib • Durvalumab • Chemotherapy • Radiotherapy • Chemotherapy and Radiotherapy | |
| Answer To Question 4: • Atezolizumab 0 • Pembrolizumab monotherapy <5 • Pembrolizumab with chemotherapy <5 • Nivolumab 0 • Osimertinib <5 • Durvalumab <5 • Chemotherapy <5 • Radiotherapy- not given at this Trust • Chemotherapy and Radiotherapy- see above | |
| Question Number 5: How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months following surgery with: • Chemotherapy • Radiotherapy • Chemotherapy + Radiotherapy | |
| Answer To Question 5: • Chemotherapy <5 • Radiotherapy- not given at this Trust • Chemotherapy + Radiotherapy- see above | |
| Question Number 6: How many Stage 2-3 resectable non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Durvalumab | |
| Answer To Question 6: • Durvalumab- 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at 91Ó°ÊÓ District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
